| Literature DB >> 35064248 |
Frank L van de Veerdonk1, Evangelos Giamarellos-Bourboulis2, Peter Pickkers3, Lennie Derde4,5, Helen Leavis6, Reinout van Crevel7, Job J Engel7, W Joost Wiersinga8, Alexander P J Vlaar9, Manu Shankar-Hari10, Tom van der Poll8, Marc Bonten5, Derek C Angus11, Jos W M van der Meer7, Mihai G Netea12,13.
Abstract
Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35064248 DOI： 10.1038/s41591-021-01643-9
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 87.241